C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease

• Published in: Experimental and therapeutic medicine Vol. 7; no. 2; pp. 443 - 446
• Main Authors: DENG, ZAI-CHUN, ZHAO, PENG, CAO, CHAO, SUN, SHI-FANG, ZHAO, FENG, LU, CHAO-YUE, MA, HONG-YING
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.02.2014; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Body mass index; C-reactive protein; Care and treatment; Chronic obstructive pulmonary disease; Diagnosis; Health risk assessment; Lung diseases, Obstructive; Measurement; Mortality; Physiological aspects; survival; China; C-reactive protein; survival; chronic obstructive pulmonary disease
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2013.1441

The present study aimed to evaluate whether circulating C-reactive protein (CRP) levels are a biomarker of systemic inflammation and a significant predictor of future chronic obstructive pulmonary disease (COPD) outcome. During the study, 116 patients with stable COPD and 35 age- and gender-matched healthy subjects with normal pulmonary function were observed. Patient follow-up was also performed to evaluate the strength of the associations between CRP levels and future outcomes. The observations from the present study showed that serum CRP levels were significantly higher in stable COPD patients than in control subjects (4.48±0.83 vs. 1.01±0.27 mg/l, respectively; P<0.05). In addition, it was identified that a serum CRP concentration of >3 mg/l is a poor prognostic variable of COPD compared with a CRP concentration of ≤3 mg/l [hazard ratio (HR), 2.71; 95% confidence interval (CI), 1.05-6.99; P<0.05]. A quantitative synthesis of four studies including 1,750 COPD patients was performed and statistically similar results were obtained (HR, 1.54; 95% CI, 1.14-2.07; P<0.01). The present study showed that circulating CRP levels are higher in stable COPD patients and, therefore, may be used as a long-term predictor of future outcomes. These observations highlight the importance of high sensitivity CRP assays in patients with stable COPD.